GlaxoSmithKline (GSK) and Genmab AS confirmed that the European Commission (EC) has granted a conditional marketing authorisation for Arzerra (ofatumumab) for the treatment of refractory chronic lymphocytic leukaemia (CLL). Ofatumumab is indicated for the treatment of CLL in patients who are refractory (have not responded) to fludarabine and alemtuzumab. Fludarabine and alemtuzumab are standard therapies currently used to treat CLL.
Genmab AS is a leading international biotechnology company focused on developing fully human antibody therapeutics.